History

Strekin concludes licensing agreement with Roche, ensuring exclusive global rights for development of pamapimod, a phase 2 clinical P38 MAPK inhibitor
Development of KIN001, a unique small molecule therapeutic
Initial preclinical models for KIN001 trigger selection of disease indications for clinical development

Pamapimod licence, KIN001 as well as corresponding data carved-out from Strekin
Kinarus AG founded based on those assets
First financing round with private investors with proceeds used to support clinical development
Kinarus files patents for KIN001 in multiple indications

Kinarus receives regulatory and ethics committee approval to launch phase 2 clinical trial of KIN001 in wet AMD as an oral therapy complementing anti-VEGF agents with the objective to extend duration between required injections
Kinarus completes clinical protocol for complementary phase 2 trial in Idiopathic Pulmonary Fibrosis (IPF), ready for regulatory submission

Composition of Matter patent granted in Europe (US decision pending) for KIN001
Second financing with private investors with proceeds used to fund the clinical development of KIN001 as well as general corporate purposes

Kinarus generates data demonstrating potent anti-viral activity of KIN001 against Sars-CoV-2
Kinarus capitalizes on KIN001 as a potentially effective COVID-19 therapy, with the advantage of targeting multiple facets of the disease given the drugs’ antiviral, anti-inflammatory, and antifibrotic activities

Kinarus receives approval from German regulatory authority to start large phase 2 clinical trial (approx. 400 patients) for the treatment of hospitalized COVID-19 patients
Third financing from private investors as well as CHF 3.0 Mio convertible loan secured used to fund the phase 2 trial of KIN001 in COVID-19 as well as the related clinical development plans
Kinarus prepares Scientific Advice (EMA) and pre-IND meeting (FDA) for agreement on clinical and technical development and launch strategy in Europe and the US
First patients dosed in Phase 2 clinical trial of KIN001 for oral treatment of hospitalized COVID-19 patients